A randomized trial of adjuvant endocrine
โ
Yasuo Nomura; Hideya Tashiro; Kazufumi Hisamatsu; Katsuko Shinozuka
๐
Article
๐
1988
๐
John Wiley and Sons
๐
English
โ 660 KB
Based on estrogen receptor (ER) status and menopausal status, operable breast cancer (International Union Against Cancer [UICC] Stage I, II, and III) patients were randomized for adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy, and the effects on the disease-free survival (DFS)